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Introduction
Intracranial hypertension, defined as an increase in ICP above 
20mmHg for longer than five minutes in non-stimulated patients, 
is due to an increase in volume of  one of  the determinants of  
ICP: brain tissue, blood volume, and cerebrospinal fluid (CSF) [1-
3]. The most dangerous consequence of  this scenario is the acute 
onset of  cerebral herniation associated with rapid worsening of  
neurological status and signs of  brain stem compression [4] Clini-
cal priority in the treatment of  these patients is to relieve high ICP 
while maintaining adequate cerebral perfusion pressure (CPP) 
and cerebral blood flow (CBF) [5]. Standard care for patients at 
risk for high ICP involves lifting the patient’s head 30 degrees 
(Fowler’s position), oxygen therapy to obtain a PaO2 greater than 
100 mmHg, fluid resuscitation with 0.9% isotonic saline solution, 
control of  water and electrolyte balance, as well as aggressive 
treatment of  hyperthermia and hyperglycemia. Pharmacologic 
therapies include the administration of  central analgesics and 
sedative-hypnotics, induction of  barbiturate coma to diminish 
the brain metabolism with resultant decrease in ICP, prophylactic 
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anti-seizure therapy [6-8], and diuretics including mannitol and/
or hypertonic saline solution to reduce brain edema [1, 9]. Neu-
rocritical care management of  intracranial hypertension encom-
passes the use of  aforementioned and other therapeutic measures 
including hemodynamic management of  CPP with vasoactive 
drugs, controlled hyperventilation to maintain PaCO2 values <35 
mmHg, ventricular drainage, and therapeutic hypothermia [1, 10]. 
However, these therapies can have significant drawbacks with re-
gards to brain perfusion and neuronal metabolism.
DC is a surgical therapy used to treat patients with high ICP re-
fractory to standard therapy (secondary DC) or those foreseen 
to be at risk for high intractable ICP (primary DC) [11]. The ra-
tionale for this approach consists of  the conversion of  a closed 
compartment into an open system with increased capacity in or-
der to limit the negative effects of  sudden increases in the volume 
of  brain components [12, 13]. Despite the potential of  this ap-
proach, its clinical efficacy is controversial [11, 13, 14].
The aim of  this retrospective case control study was to report 
the effects of  primary DC on the mortality rate and long term 
functional status (Glasgow Outcome Scale at discharge and 6th 
months) of  patients with increased ICP. We also investigated the 
need for NCC therapies (vasoactive drugs, controlled hyperven-
tilation, barbiturate coma) in patients who underwent DC com-
pared to those medically managed alone for elevated ICP.
Methods
The protocol and consent forms were approved by the Institu-
tional Review Board for Human Research of  the University of  
Rome “La Sapienza”. From January 2009 to January 2012, demo-
graphic and clinical data were collected and analyzed retrospec-
tively comparing patients treated with primary DC and matched 
controls treated with standard medical therapies alone. Patients 
with severe traumatic brain injury, massive stroke or hemorrhage, 
bilateral fixed mydriasis, and a Glasgow Coma Scale (GCS) of  3 or 
those with significant comorbidities were excluded from the study 
because of  the overall poor prognosis independent of  therapeutic 
interventions.
Upon admission to the neurosurgical intensive care unit, ICP 
monitoring devices were installed in all cases. Intra-parenchymal 
catheters (Codman ICP Monitoring System, ICP Express) were 
placed on the most damaged side of  the brain or on the right 
hemisphere in cases of  diffuse bilateral damage.  A neurologi-
cal examination with GCS was conducted in each patient when 
metabolic and hemodynamic stability was restored and before any 
pharmacological sedation was administered. ICP values were as-
sessed on admission to the neurosurgical ICU, before decompres-
sion, at 24h and 72h after decompression in the DC group and 
at corresponding time points in the control patients. All patients 
were continuously monitored (Siemens SC 7000, Sweden) with 
a 3-lead ECG to measure heart rate (HR), invasive mean arterial 
pressure (MAP), arterial oxygen saturation (SpO2) and end-tidal 
CO2 (ETCO2). Patients were intubated and mechanical ventilation 
(synchronized intermittent mandatory ventilation (SIMV) modal-
ity with tidal volume of  7ml/kg) was adjusted for respiratory rate, 
an inspiratory fraction of  O2 ensuring a PaO2 between 100 and 
200 mmHg, and an end-tidal volume of  CO2 (EtCO2) between 35 
and 40 mmHg. Positive end-expiratory pressure (PEEP, 7 ± 3 cm 
H20) was utilized as tolerated in patients to optimize ventilatory 
pattern and reduce the incidence of  pulmonary infections. Each 
patient received fluid resuscitation therapy with isotonic saline so-
lution (1ml/kg/h) and, whenever indicated, blood replacement 
with appropriate blood components. In patients with fever (T>38 
°C), paracetamol (1g every 6-8 hours) or diclofenac (0.05 mg/
kg/h) was continuously infused while in cases of  refractory fe-
ver, an electric cooling device (fan or cooling blanket) was used. 
To reduce the cerebral metabolic rate and better control the ICP, 
propofol (3 mg/kg/h) and remifentanil (0.25 mcg/kg/min) were 
continuously infused. In cases where this was insufficient, mida-
zolam (0.1-0.2 mg/kg/h) was added.
In patients undergoing primary DC, craniectomy method was se-
lected by neurosurgeons based on CT scan indications. Unilateral 
hemicraniectomy (fronto-temporo-parietal flap) was performed 
when hemispheric edema was evident while bilateral craniectomy 
(bifrontal flap) was performed in cases of  diffuse edema. In both 
craniectomy methods, a large bone flap was removed followed by 
duraplasty to allow further expansion of  the brain. The exposed 
brain was then covered by either a homologous pericranial auto-
graft or by a Gortex graft. The bone flap was stored in a freezer at 
-18°C until reinsertion, which occurred in all surviving patients an 
average of  four months after the DC (range 1-7 months).
Patients who underwent primary DC were matched with individu-
als who possessed similar demographic and pre-intervention ICP 
values who had been treated with standard NCC management 
alone to create a control group. NCC management of  elevated 
ICP (used in combination with DC in the study group or alone in 
the control group) utilized a sequential approach: mannitol 18% 
via intermittent intravenous bolus at a dose of  0.25-1 g/kg (and, 
if  necessary for additional diuresis, furosemide 20-40 mg/day), 
controlled hyperventilation to achieve an EtCO2 between 28 and 
30 mmHg, and barbiturate coma with thiopental (3-5 mg/kg/h) 
to achieve a burst suppression state documented with EEG moni-
toring. A MAP> 90 mmHg was maintained to ensure a cerebral 
perfusion pressure (CPP) of  no less than 70 mmHg. According 
to standard practice, if  CPP fell below 70 mmHg, a continuous 
infusion of  norepinephrine (0.03-0.1 mcg/kg/min) was started 
and titrated to achieve this target.
The primary endpoints were all-cause mortality and patient func-
tional status both at discharge and at a 6-month follow-up. Neu-
rological functional status was evaluated using the Glasgow Out-
come Scale [15]. A GOS score of  4 (moderately disabled) or 5 
(independent) was considered favorable while a GOS of  3 (severe 
disability) or 2 (persistent vegetative state) was considered unfa-
vorable. Functional evaluation follow-up at 6-months was record-
ed by a single expert neurologist after interviewing the patients as 
well as their relatives, attending physician, family physician doctor, 
or rehabilitation physician. These interviews were conducted in 
the outpatient setting by the physician in charge. Secondary end-
points were ICP values at the established time points and overall 
utilization and escalation of  ICP-modulating NCC therapies in 
the DC and control groups including therapeutic hyperventilation 
and PEEP optimization as well as the use of  barbiturate coma, 
furosemide, and norepinephrine.
Statistical Analysis
All values are reported as a mean ± SD or as a percentage. A 
paired-samples t-test was used to compare ICP values before and 
after intervention. Likewise, this test also was used to compare 
hemodynamic variables and utilization of  NCC interventions 
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between the study groups. Percentage differences were evaluated 
with a chi-square or Fisher’s exact test. SPSS 12.0 for Windows 
was used for the analysis. A p value < 0.05 was considered statisti-
cally significant.
  
Results
From January 2008 to January 2012, 66 patients were treated with 
primary DC for ICP elevation but only 34 met study inclusion 
requirements. Thirty-four additional patients who possessed simi-
lar demographic parameters (weight, height, BMI, gender, race), 
comorbid conditions, as well as pre-intervention elevated ICP val-
ues, who were treated with standard medical therapies alone, were 
matched as a control group. The patients’ age, gender, injury type 
and GCS values at admission are shown in Table 1.
There was no significant difference in mortality rate between the 
two groups (29.4% (10 patients) in the DC group vs. 47% (16 
patients) in the standard care group (p = 0.212)). Of  note, the 
majority of  deaths occurred in the first 48h after admission to the 
ICU. The functional outcome of  all surviving patients also was 
assessed. In the DC group, 62.5% (15 patients) had a good out-
come at discharge (GOS 4-5) and 37.5% (9 patients) had a poorer 
one (GOS 2-3). In the standard care group, 27.7% (5 patients) 
had a good outcome and 72.2% (13 patients) had a poorer one. 
These results were statistically significant demonstrating that DC 
patients had better outcomes at the time of  discharge (p = 0.033). 
At the 6 month follow-up, data were similar, and the significant 
difference between the two groups was maintained. In the DC 
group, 66.6% (16 patients) had a good outcome versus 33.3% (8 
patients) of  poorer outcome, while only 33.3% (6 patients) in the 
standard care group had a good outcome (p = 0.033).
The ICP values on admission were similar in both groups (28.7 ± 
2.4 vs. 27.2 ± 3.5, p > 0.05), however, 24 h after decompression, 
the ICP values were significantly lower in the DC group (11.2 ± 
2.4 vs. 17.5 ± 3.2, p < 0.0005). At 72 h after decompression, the 
difference was smaller but remained statistically significant (13.5 
± 3.6 vs. 16.7 ± 2.3; p < 0.0005). All patients received anti-edema 
therapy by infusion of  mannitol four times daily, but only 11 pa-
tients (32.3%) in the DC group required addition of  furosem-
ide, significantly less than the 21 patients (61.7%) who required 
furosemide in the standard care group (p = 0.028). Additionally, 
the duration of  furosemide therapy was shorter in the DC group, 
avoiding collateral effects of  the drug (96 ± 48 h vs. 168 ± 72 h; 
p = 0.006). 
Some patients required an infusion of  norepinephrine to ensure 
an adequate CPP. There was a significant difference between the 
study groups both in administered doses and infusion time. In the 
DC group, fewer patients needed norepinephrine infusion com-
pared to patients not treated with DC: 14 DC patients (41.7%) 
required an infusion of  norepinephrine of  0.05 ± 0.02 mcg/kg/
min while 23 patients (67.6%) in the standard care group required 
an infusion of  0.1 ± 0.05 mcg/kg/min (p = 0.001). Additionally, 
in patients in the DC group, lower rates of  norepinephine infu-
sion were required to maintain adequate CPP. The infusion time 
in the DC group also was lower than that of  the standard care 
group (21 ± 8 h vs. 36 ± 6 h; p < 0.0001).
There were significant differences between the study groups in 
the use of  therapeutic hyperventilation and barbiturate coma. 
Therapeutic hyperventilation was used less frequently in the DC 
group, 8 patients (23.5%) versus 18 patients (52.9%) (p = 0.024). 
The use of  barbiturate coma followed the same trend: 4 patients 
(11.7%) in DC group versus 12 patients (35.2%) in the standard 
care group (p = 0.043). Additionally, the duration of  barbiturate 
coma was significantly lower in the DC group, 22 ± 6 h vs. 35 ± 
6 h (p = 0.03).  
The use of  PEEP (7 ± 3 cm H2O) to optimize patient ventilatory 
pattern and reduce the incidence of  pulmonary infections was es-
pecially useful in the DC group as more patients were able to tol-
erate it compared to the standard care group, 26 patients (76.4%) 
vs. 16 patients (47%) respectively (p = 0.024). This difference was 
Table 1. Demographic and clinical data of  patients treated with decompressive craniectomy and with standard care therapy
Data DC CG
Number of  patients 34 34
Age† 47±9 52±8
Male/Female 20/14 24/10
Type of  Injury
TBI 15 TBI 12
SDE 4 SDE 5
SAH 7 SAH 5
ICH 5 ICH 9
AIS 3 AIS 4
GCS at admission
GCS 3-8: 9 GCS 3-8: 8
GCS 9-12: 15 GCS 9-12: 14
GCS 13-15: 10 GCS 13-15: 12 
† The values are expressed in mean ± SD
DC=Decompressive Craniectomy; CG=Control Group; TBI: Traumatic Brain Injury; SDH: Subdural Hematoma; SAH: Subarachnoid 
Hemorrhage; ICH: Intracerebral Hemorrhage; AIS: Acute Ischemic Stroke; GCS: Glasgow Coma Scale. 
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likely due to the effect of  PEEP on intracranial pressure, limiting 
its use in patients not undergoing a craniectomy.
Discussion
This study demonstrated that patients treated with DC had a more 
favorable neurological outcome than patients treated by medical 
therapy alone. This was evident both at discharge and after six 
months. Moreover, post-therapy ICP was significantly lower in 
patients treated with DC, and patients in the DC group needed 
fewer intensive medical therapies such as hyperventilation, barbi-
turate coma, diuretic therapy and catecholamine administration 
thus reducing the incidence of  associated adverse effects and 
neurotoxicity. This study supports published evidence describing 
better ICP control, less intensive therapy, and improvement of  
neurological outcome in patients who undergo DC [11, 13].
Hemodynamic Management
The principal objective of  DC is to normalize ICP and restore a 
favorable level of  CBF [11-13]. Reduction of  elevated ICP fol-
lowing DC can be explained by the increase in intracranial com-
pliance with establishment of  a more favorable pressure/volume 
ratio which promotes restoration of  CBF. Cerebral blood flow 
increases bilaterally even if  the decompression is unilateral; more-
over, there are no substantial differences in blood flow following 
a bilateral decompression. Doppler flowmetry studies show an 
immediate and stable normalization of  global cerebral hemody-
namics for, at least, the first 48 hours following the completion of  
the procedure [16]. This suggests that decompression allows for 
rapid recruitment of  capillaries and microcirculation zones that 
were compressed and poorly functioning in intracranial hyperten-
sive conditions. In patients in whom ICP does not normalize after 
DC, the mortality rate is extremely high indicating a major and 
progressive extension of  ischemic cerebral damage [17].
In patients with elevated ICP, clinical evidence suggests that CPP 
should be maintained at a minimum of  70 mm Hg. It is therefore 
imperative to prevent systemic arterial hypotension by assuring 
a MAP of  no less than 90 mm Hg [1, 18]. The maintenance of  
elevated hemodynamic values often demands continuous infu-
sion of  vasoactive amines and/or volume overload [19]. This ap-
proach is potentially dangerous as it can increase cerebral edema 
or cause cardiac decompensation, pulmonary edema, metabolic 
acidosis and coagulopathy [20-23]. Overuse of  the saline solu-
tion may cause a hyperchloremic metabolic acidosis with related 
multiple adverse effects on metabolic and enzymatic function. 
These complications include decreased myofibril contractility and 
altered membrane ion channel function with consequent systemic 
vasodilatation and hypotension, arrhythmias, increase of  pulmo-
nary vascular resistance, as well as reduction of  cardiac output 
and catecholamine resistance. Additionally, overly aggressive fluid 
resuscitation can also alter glucose metabolism and oxygen avail-
ability [24]. In turn, colloids such as dextran, hydroxyethyl starch 
(HES) and albumin, are related with a different type of  adverse 
effects. Their use is associated with a negative impact on hemo-
coagulation caused by antiplatelet effects of  these solutions and 
dilution coagulopathy [22, 25]. Various clinical studies comparing 
the effects of  CBF maintenance strategies have failed to associate 
favorable neurological outcomes with these therapies and actually 
suggest a five-fold increase in the incidence of  adult respiratory 
distress syndrome (ARDS). This study indicates that treating el-
evated ICP with DC to improve CBF results in fewer complica-
tions than catecholamine use and/or aggressive volume resuscita-
tion to elevate MAP, CPP and ultimately CBF [21].
Mechanical Ventilation
Mechanical ventilation can be life-saving as it provides airway 
protection and optimization of  gas exchange but it also has as-
sociated complications that can worsen prognosis. The principal 
adverse events include Acute Lung Injury (ALI) / ARDS, pulmo-
nary edema, pneumonia, and ventilator-induced lung injury (VLI).
Mechanical hyperventilation can become a necessary treatment 
of  elevated ICP during the initial acute management of  elevated 
ICP or as a life-saving maneuver to treat acute brain herniation. 
However it’s prolonged use is associated with tissue hypoxia, de-
creased efficacy in controlling ICP due to readjustment of  intrac-
ranial acid-base balance, and worse outcome. The Brain Trauma 
Foundation recommendations clearly focus on prevention of  hy-
poxia, maintenance of  CPP around 70 mm Hg as well as an ICP 
under the threshold value of  20 mm Hg.
The use of  PEEP in patients at risk of  developing intracranial 
hypertension has been widely debated as it may increase ICP. The 
additional expiratory pressure support furnished by PEEP is re-
flected in the central venous compartment, interfering with the 
refilling of  the vena cava causing an increase in cerebral venous 
pressure [26]. Alternatively, PEEP can increase functional residual 
capacity and prevent atelectases with alveolar recruitment which 
can optimize gas exchange and reestablish a more favorable ven-
tilation/perfusion relationship leading to PaCO2 reduction and 
a decrease in ICP [27]. Additionally, PEEP can be beneficial by 
lowering O2 toxicity risk secondary to lower FiO2 allowance [28]. 
This study demonstrated that the management of  intracranial hy-
pertension along with DC helped to avoid potentially hazardous 
hyperventilation-associated complications as hyperventilation was 
utilized significantly less in the DC group compared to the stand-
ard care group. Also, PEEP was better tolerated in the DC group 
allowing for potential benefits such as decreased lung infection 
risk without concern for increased ICP during DC- induced ICP 
normalization.
Neuroprotection
One of  the most frequently employed techniques for neuropro-
tection in patients with elevated ICP is barbiturate coma. De-
spite controversies regarding the ability of  barbiturate coma to 
improve the long-term neurological outcome in patients with in-
tractable intracranial hypertension, it still serves as a last resort in 
this patient population. Currently, high-dose barbiturate admin-
istration is recommended to control elevated ICP refractory to 
maximum standard medical and surgical treatment [29]. The ap-
plication of  barbiturate coma should be limited to hemodynami-
cally stable patients who have a margin of  neurological recovery. 
Barbiturates (sodium thiopental is used most often) cause a dose 
dependent reduction of  neuronal activity, CBF as well as neuronal 
metabolic O2 and glucose requirements. As barbiturate adminis-
tration increases, there is a corresponding increase in intracellular 
chlorine influx via gamma aminobutyric acid (GABA)-A recep-
tors and blockade of  AMPA receptors. The net effect translates 
to neuronal hyperpolarization and a major and diffuse depres-
sion of  neuronal activity witnessed by electro-encephalographic 
variation [30]. The decrease in cerebral electrical activity is ob-
served as burst suppression on EEG; thus constant monitoring 
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is mandatory until the minimal effective barbiturate infusion dose 
is confirmed [31]. Potential adverse effects include: myocardial 
depression, peripheral vasodilatation with hypotension, a reduc-
tion in venous jugular oxygen saturation, immunosuppression, 
and leucopenia with increased incidence of  infection [32]. Our 
results showed that DC decreased the necessity of  barbiturate 
coma, again avoiding potential negative effects associated with 
adjunct therapies.
Complications
There are several complications associated with DC. Preoperative 
risk is primarily tied to the patient’s clinical condition. Post-proce-
dural complications can be early or late and should be considered 
by every intensivist concerned with neuro-resuscitation.
Early Complications
Bleeding can start during the surgical procedure and continue into 
the immediate postoperative period causing hematoma, cerebral 
edema and onset of  relentless elevation of  ICP. There is a 3–5% 
incidence of  hematoma and bleeding [33]. External cerebral her-
niation can occur as well. This complication frequently develops 
within the first days that follow DC and is caused by insufficient 
resection to accommodate post-procedural brain expansion. 
Compression of  the venous vasculature in the herniated cortex 
can lead to hemorrhagic infarction of  the herniated tissue [33]. 
Additionally, increased compliance of  cerebral tissue with room 
to expand following DC causes an increase in the hydrostatic gra-
dient which can increase interstitial edema. An imbalance in CSF 
circulation also can lead to the formation of  a subdural hygroma 
ipsilateral to the craniectomy [34].
Late Complications
There is a greater incidence of  postoperative infection includ-
ing meningitis and subdural empyema following DC compared 
to other neurosurgical procedures. The procedure can lead to le-
sions of  the superficial temporal artery with a negative impact on 
scalp perfusion and wound scarring. Furthermore, the initial DC 
obligates a second surgical intervention in order to replace the 
removed bone, adding additional risks [35]. Formation of  an ob-
structive hydrocephalus is another possible complication of  DC, 
as well as the “Trephine” syndrome, consisting of  a contralateral 
(to the DC) upper limb paresis developing months after the sur-
gery. It may be caused by a contusion of  the cerebral parenchy-
ma and an anomalous CSF circulation that follows the DC. The 
symptoms generally revert with bone repositioning and adequate 
physiotherapy [36].
Conclusions
Clinical priorities in elevated ICP management are the mainte-
nance of  CPP along with adequate oxygen delivery to prevent sec-
ondary hypoxic damage. In such patients with elevated ICP, DC is 
an effective way to normalize ICP levels and re-establish optimal 
cerebral perfusion while reducing the need for aggressive medical 
therapies and associated cardiovascular and pulmonary compli-
cations. Furthermore, patients treated with DC are less likely to 
need neuro-protective techniques such as barbiturate coma. Neu-
rological outcome in patients treated with DC was found to be 
better compared with patients receiving only medical treatment. 
DC redefines clinical priorities for the management of  patients at 
risk for intracranial hypertension; shifting from cerebral hernia-
tion avoidance to prevention of  secondary cerebral damage. Such 
a treatment should be considered in all patients with elevated ICP 
refractive to initial conservative management and in those at risk 
for developing high intractable ICP.
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